[Skip to Content]
[Skip to Content Landing]
October 1997

Comparing Topical Scabietic Treatments Will Soon Become Extinct

Arch Dermatol. 1997;133(10):1314. doi:10.1001/archderm.1997.03890460140025

We noted the interchange between Franz et al1 and Downs2 in recent issues of the Archives concerning the available topical scabietic agents that are currently used. However, with the Food and Drug Administration's approval of ivermectin (Stromectol, Merck & Co Inc, West Point, Pa) in November 1996, a new era of scabietic therapeutics began. Ivermectin is an anthelmintic used extensively in veterinary medicine for a wide range of nematode, insect, and acarine parasites, including Sarcoptes scabiei in animals.3 We use this drug routinely every 2 months for all the Arabian horses on our farm to control any potential parasitic infection. In fact, ivermectin is sold over-the-counter at farm supply stores, tack shops, grain elevators, and via stock catalogs for animal use. The drug has also been used in more than 6 million people for diseases, including onchocerciasis, strongyloidiasis, loiasis, bancroftian filariasis, and cutaneous larva migrans.

There already